IP Library Granted Patent US 10,792,258
Granted Patent B2
US 10,792,258 · App. 16/371,670 · Granted Oct 6, 2020

Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne

Inventors: José Agustín Rogelio Magaña Castro (Mexico City, MX); Laura Vázquez Cervantes (Mexico City, MX); Pedro Peña Santoyo (Mexico City, MX)
Assignee: Excalibur Pharmaceuticals, Inc.
A61K31/191A61K8/365A61K8/46A61K31/10A61Q17/005A61Q19/008A61Q19/10A61K2800/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,792,258
App. No.
16/371,670
Granted
Oct 6, 2020
Kind
B2
Abstract

The invention refers to an antimicrobial, exfoliating and seboregulating hydrosoluble composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid), which acts removing bacteria affecting the skin including those caused by acne, said composition also provides deep cleansing, exfoliating action, reduces epidermal cohesion facilitating cellular change, preventing the occurrence of several forms of acne in the skin and additionally producing seboregulating effects by avoiding blockage of sebaceous glands.

Claims (20)

1. A hydrosoluble, topical pharmaceutical composition comprising from 0.001 to 10% by weight of diallyl disulfide modified oxide, from 1 to 12% by weight of glycolic acid, from 0.3 to 24% by weight of one or more surfactants, from 0.3 to 10% by weight of a moisturizing agent, from 0.2 to 10% by weight of an aromatizing agent, and from 40 to 70% by weight of an aqueous solvent.

2. The composition according to claim 1 , wherein the surfactants are selected from the group consisting of linear alkylbenzensulfonates and ionic alkyl sulfates.

3. The composition according to claim 1 , wherein the surfactants are selected from the group consisting of sodium lauryl sulfate, sodium lauryl ether sulfate, and ammonium lauryl sulfate.

4. The composition according to claim 1 , wherein the moisturizing agent is selected from the group consisting of ethylene glycol, propylene glycol, glycerin, sorbitol, low molecular weight polyethylenes, polyoxyethylated glycerols, and polyoxyethylated sugars.

5. The composition according to claim 1 , wherein the solvent is selected from water and water-hydrosoluble alcohol mixtures.

6. A method for removing or reducing acne in a subject in need thereof, the method comprising administering the hydrosoluble topical pharmaceutical composition of claim 1 to skin of the subject.

7. A topical pharmaceutical composition, comprising:

a) diallyl disulfide modified oxide;

b) glycolic acid;

c) a surfactant selected from the group consisting of (i) sodium lauryl sulfate, (ii) sodium lauryl ether sulfate, and (iii) sodium lauryl sulfate and sodium lauryl ether sulfate; and

d) a moisturizing agent selected from the group consisting of glycerin, ethylene glycol, and sorbitol.

8. The composition of claim 7 , wherein the diallyl disulfide modified oxide is 0.8% by weight of the composition.

9. The composition of claim 7 , wherein the diallyl disulfide modified oxide is 1.0% by weight of the composition.

10. The composition of claim 7 , wherein the moisturizing agent is glycerin.

11. The composition of claim 7 , wherein the surfactant is 20% by weight of the composition.

12. The composition of claim 7 , wherein the moisturizing agent is 0.4% by weight of the composition.

13. The composition of claim 7 , wherein the moisturizing agent is 0.5% by weight of the composition.

14. The composition of claim 7 , wherein the glycolic acid is 11.42% by weight or 11.6% by weight of the composition.

15. The composition of claim 1 , wherein the composition kills Propionibacterium acnes.

16. The composition of claim 7 , wherein the composition kills Propionibacterium acnes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: GRUPO MEDIFARMA S.A. DE C.V.
To: EXCALIBUR PHARMACEUTICALS, INC.
Reel/Frame 053418/0721 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2019
From: MAGAÑA CASTRO, JOSÉ AGUSTÍN ROGELIO; VÁZQUEZ CERVANTES, LAURA; PEÑA SANTOYO, PEDRO
To: GRUPO MEDIFARMA S.A. DE C.V.
Reel/Frame 049312/0830 →
Priority Claims (1)
MX MX/A/2012/009806 · Aug 23, 2012 · national
Continuity (3)
Continuation 16008210 · Jun 14, 2018
Continuation 14421616
Related Publication 20190290606A1 · Sep 26, 2019
Cited By (2)
US 12,667,561 US 12,702,713